We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $580M
1-Year Est. Return 29.81%
This Fund
S&P 500
This Quarter Est. Return
-1.98%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$580M
AUM Growth
-$29.5M
Cap. Flow
-$5.55M
Cap. Flow %
-0.96%
Top 10 Hldgs %
70.73%
Holding
51
New
5
Increased
16
Reduced
15
Closed
15

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$45.5M
2
BSX icon
Boston Scientific
BSX
+$25.8M
3
IRTC icon
iRhythm Holdings
IRTC
+$18.1M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$14M
5
MLYS icon
Mineralys Therapeutics
MLYS
+$12.3M

Top Sells

Rank Stock Value
1
PRCT icon
Procept Biorobotics
PRCT
+$42M
2
MGTX icon
MeiraGTx Holdings
MGTX
+$25.2M
3
WGS icon
GeneDx Holdings
WGS
+$24.9M
4
KURA icon
Kura Oncology
KURA
+$12.6M
5
CON
Concentra Group Holdings
CON
+$10.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.79%
2 Technology 0.21%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LKFT
1
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$61.3M 10.56%
2,043,344
+493,344
+32% +$14M
JANX icon
2
Janux Therapeutics
JANX
$1.1B
$58.4M 10.07%
3,804,481
+254,481
+7% +$3.69M
NKTR icon
3
Nektar Therapeutics
NKTR
$2.48B
$56.5M 9.74%
810,000
+75,000
+10% +$5.49M
BSX icon
4
Boston Scientific
BSX
$67.9B
$54.2M 9.34%
1,270,273
+474,726
+60% +$25.8M
STTK icon
5
Shattuck Labs
STTK
$707M
$41.3M 7.12%
5,957,877
+953,438
+19% +$5.95M
INSM icon
6
Insmed
INSM
$25.9B
$40M 6.9%
+375,609
New +$45.5M
ALNY icon
7
Alnylam Pharmaceuticals
ALNY
$31.7B
$29.5M 5.09%
98,080
+22,080
+29% +$6.66M
SNDX icon
8
Syndax Pharmaceuticals
SNDX
$1.74B
$26.2M 4.52%
1,200,000
+430,000
+56% +$8.94M
KURA icon
9
Kura Oncology
KURA
$1.13B
$22.2M 3.82%
2,021,964
-1,334,736
-40% -$12.6M
ALKS icon
10
Alkermes
ALKS
$7.95B
$20.7M 3.56%
394,389
-119,243
-23% -$4.66M
IRTC icon
11
iRhythm Holdings
IRTC
$3.96B
$19.7M 3.39%
165,500
+155,500
+1,555% +$18.1M
VEEV icon
12
Veeva Systems
VEEV
$44.8B
$18.8M 3.25%
106,200
+19,720
+23% +$3.25M
ZYME icon
13
Zymeworks
ZYME
$2.02B
$17.6M 3.04%
674,434
+135,385
+25% +$3.44M
ABVX
14
Abivax
ABVX
$9.89B
$14.3M 2.47%
107,394
+2,394
+2% +$271K
CRNX icon
15
Crinetics Pharmaceuticals
CRNX
$9B
$14M 2.42%
374,666
+24,666
+7% +$917K
MLYS icon
16
Mineralys Therapeutics
MLYS
$2.26B
$12.1M 2.09%
+449,795
New +$12.3M
ADCT icon
17
ADC Therapeutics
ADCT
$146M
$8.37M 1.44%
7,824,749
-475,251
-6% -$1.39M
ICUI icon
18
ICU Medical
ICUI
$4.38B
$7.48M 1.29%
51,000
+23,550
+86% +$3.07M
ISRG icon
19
Intuitive Surgical
ISRG
$132B
$6.76M 1.16%
17,000
+13,000
+325% +$5.68M
CRBP icon
20
Corbus Pharmaceuticals
CRBP
$211M
$6.1M 1.05%
650,000
-47,108
-7% -$446K
PRCT icon
21
Procept Biorobotics
PRCT
$1.19B
$6.06M 1.04%
268,269
-1,676,731
-86% -$42M
WGS icon
22
GeneDx Holdings
WGS
$2.57B
$5.87M 1.01%
85,500
-437,963
-84% -$24.9M
OPCH icon
23
Option Care Health
OPCH
$3.58B
$5.68M 0.98%
+270,716
New +$6.29M
OKUR
24
OnKure Therapeutics
OKUR
$153M
$4.46M 0.77%
978,992
-1,175,389
-55% -$5.04M
EBS icon
25
Emergent Biosolutions
EBS
$303M
$3.85M 0.66%
459,952
-179,166
-28% -$1.5M
1
2 3

Similar funds

SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
CA
COFG Advisors Oak Brook, Illinois $579M AUM

Prosight Management's Q2 2026 Portfolio in Review

As of Q2 2026, Prosight Management held 51 positions worth $580M, down 4.8% from $610M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Prosight Management's Q2 2026 filing shows 5 new, 16 increased, 15 reduced and 15 closed positions. Its largest new stake was Insmed: 375,609 shares worth $40M. The largest sale was Procept Biorobotics, an estimated $42M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Technology and Industrials.

  • Prosight Management's largest Q2 2026 buy was Insmed: 375,609 shares worth $40M.
  • Prosight Management added most to Boston Scientific in Q2 2026, an estimated $25.8M increase.
  • Prosight Management's biggest Q2 2026 reduction was Procept Biorobotics, cutting an estimated $42M.
  • Prosight Management fully exited Concentra Group Holdings in Q2 2026, selling an estimated $10.8M.
  • Prosight Management's ten largest holdings make up 71% of its $580M portfolio in Q2 2026.
  • Prosight Management opened 5 new positions and closed 15 in Q2 2026.
  • Prosight Management's portfolio value fell 4.8% quarter-over-quarter to $580M.

Based on Prosight Management's 13F filing for Q2 2026, filed 14 Aug 2026.